Pimavanserin in the Treatment of Parkinson's Disease Psychosis: Meta-analysis and Meta-regression of Randomized Clinical Trials.

ABSTRACT:

Background

Up to 60 percent of patients with Parkinson's disease (PD) develop Parkinson's disease psychosis (PDP). PDP is associated with a significant economic burden. The management of PDP has been divided into two approaches-one focuses on decreasing the doses of anti-Parkinsonian medications and the other involves prescribing atypical antipsychotics. Of these atypical antipsychotics, pimavanserin is United States (US) Food and Drug Administration (FDA)-approved specifically for the treatment of PDP.

Objective

The goal was to evaluate the safety and efficacy of pimavanserin in the treatment of PDP based on data from randomized clinical trials.

Methods

All the articles, which assessed pimavanserin's effect on the treatment of PDP, were retrieved from Google Scholar,

SUBMITTER: Mansuri Z 

PROVIDER: S-EPMC8970241 | biostudies-literature | 2022 Jan-Mar

REPOSITORIES: biostudies-literature